Quick Answer
Xilio Therapeutics, Inc. reported Revenue (ASC 606) of $43.77 million for fiscal year 2025.
Xilio Therapeutics, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $43.77M | +589.9% |
| 2024 | $6.34M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $19.07M | +742.5% | +135.8% |
| June 30, 2025 | $8.08M | +243.0% | +175.9% |
| March 31, 2025 | $2.93M | — | +29.5% |
| September 30, 2024 | $2.26M | — | -4.0% |
| June 30, 2024 | $2.36M | — | — |
- Xilio Therapeutics, Inc. showed an increase of +589.9% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2024–2025 period, Xilio Therapeutics, Inc.’s revenue (asc 606) has grown by 589.9% (from $6.34 million to $43.77 million).
- The most recent figure is from Xilio Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: